Category: Biosimilars
Global Biosimilars
-
Ankylosing Spondylitis Global Market Report 2023 Including: 1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Disease-Modifying Anti-Rheumatic Drugs (DMARDS); Biological Therapies; Steroids; Physical Therapies; Surgery 2) By Molecule: Biologics; Biosimilar; Small Molecules 3) By Route of Administration: Parenteral; Oral 4) By Application: Juveniles; Adults 5) By End User: Hospitals; Clinics; Research Laboratoriesrs Covering: Pfizer Inc.; Johnson & Johnson Pvt. Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
... of Administration: Parenteral; Oral4) By Application: Juveniles; Adults5) By End User: Hospitals; Clinics; Research LaboratoriesrsCovering: Pfizer Inc.; Johnson & Johnson Pvt. Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG Ankylosing Spondylitis Global Market Report ... Read More
-
Biopharmaceutical CMO Market Forecasts to 2030 – Global Analysis By Product (Biologics, Biosimilars and Other Products), Source, Service and By Geography
... in 2023 and is expected to reach $39.41 billion by 2030 growing at a CAGR of 14.6% during the forecast period. A biopharmaceutical CMO, often referred to as a contract manufacturing organization, is a business ... Read More
-
Biosimilars Market Forecasts to 2030 – Global Analysis By Drug Class (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins and Other Drug Classes), Manufacturing Type (In-house Manufacturing and Contract Manufacturing), Technology (Mass Spectroscopy, Chromatography, Monoclonal Antibody Technology and Other Technologies), Application, End User and By Geography
... and Other Technologies), Application, End User and By GeographyAccording to Stratistics MRC, the Global Biosimilars Market is accounted for $23.9 billion in 2023 and is expected to reach $100.2 billion by 2030 growing at a ... Read More
-
Oncology Biosimilars Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
... reach US$ 14.7 Billion by 2028, exhibiting a growth rate (CAGR) of 21.6% during 2023-2028. Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation ... Read More
-
2023 Global Biosimilar Contract Manufacturing Industry (2029 Outlook)
... Market Outlook reports provide market size data for a three-year historical trend (2017-2020), a three-year forecast estimate trends (2021-2023), and a five-year outlook projection (2024-2029) for 46 countries. Market and product shipments include the total ... Read More
-
2023 Global Biosimilar Monoclonal Antibodies Market Industry (2029 Outlook)
... Global Advanced Market Outlook reports provide market size data for a three-year historical trend (2017-2020), a three-year forecast estimate trends (2021-2023), and a five-year outlook projection (2024-2029) for 46 countries. Market and product shipments include ... Read More
-
Global Biosimilars Market - 2023-2030
... is expected to exhibit a CAGR of 12.8% during the forecast period 2023-2030. Biosimilars provide an opportunity to increase patient access to biological therapies by offering more affordable alternatives while maintaining the same therapeutic benefits. ... Read More
-
2023 Global Forecast for Oncology Biosimilars Market (2024-2029 Outlook)-High Tech & Emerging Markets Report
... product or service category is within the NAICS Medical Laboratories industry. The product or service category is within the NAICS Medical Laboratories industry. The global market is expected to increase from USD xx billion in ... Read More
-
Impact of Inflation on the Healthcare Sector by Physicians Perspective, Patient Treatment, Regional Analysis, Drug Prices and Treatment Costs - Thematic Intelligence
... continues to examine the impact of inflation on healthcare systems, patients, and HCPs. The report provides an overview of the current and future outlook of the healthcare sector, government policies, innovative technologies, and initiatives that ... Read More
-
Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region – Global Forecast to 2028
... billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% during the forecast period. Factors such as regulatory approvals, favorable reimbursement policies, rising demand for cost effective biosimilars is driving the ... Read More
-
Global Biologics and Biosimilars Market 2023 by Company, Regions, Type and Application, Forecast to 2029
... million in 2022 and is forecast to a readjusted size of USD 843370 million by 2029 with a CAGR of 8.3% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while ... Read More
-
Global Biologics and Biosimilars Supply, Demand and Key Producers, 2023-2029
... the forecast period (2023-2029). Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the ... Read More
-
Global Lucentis (Ranibizumab) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of -2.7% from 2023 to 2029. United States market for Lucentis (Ranibizumab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Humira Biosimilar Market Growth 2023-2029
... CAGR of 13.0% from 2023 to 2029. The introduction of Humira biosimilars is expected to increase competition in the market, leading to lower prices and improved access to treatment for patients. The availability of biosimilars ... Read More
-
Global Herceptin (Trastuzumab) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of 5.0% from 2023 to 2029. United States market for Herceptin (Trastuzumab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Bevacizumab Monoclonal Antibody Biosimilar Market Growth 2023-2029
... to grow at a CAGR of -15.0% from 2023 to 2029. United States market for Bevacizumab Monoclonal Antibody Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Epogen and Biosimilar Market Growth 2023-2029
... at a CAGR of -3.3% from 2023 to 2029. United States market for Epogen and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % ... Read More
-
Global Neulasta (Pegfilgrastim) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of 6.7% from 2023 to 2029. United States market for Neulasta (Pegfilgrastim) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Adalimumab (Humira) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of -5.3% from 2023 to 2029. The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication ... Read More
-
Global Thyrogen and Biosimilar Market Growth 2023-2029
... at a CAGR of 16.3% from 2023 to 2029. United States market for Thyrogen and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % ... Read More
-
Global Avastin Biosimilar Market Growth 2023-2029
... CAGR of -15.0% from 2023 to 2029. United States market for Avastin Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through ... Read More
-
Global Enbrel (Etanercept) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of 3.4% from 2023 to 2029. United States market for Enbrel (Etanercept) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Remicade (Infliximab) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of 5.8% from 2023 to 2029. United States market for Remicade (Infliximab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Rituxan (Rituximab) and Biosimilar Market Growth 2023-2029
... to grow at a CAGR of 3.6% from 2023 to 2029. United States market for Rituxan (Rituximab) and Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a ... Read More
-
Global Enbrel (Etanercept) Biosimilar Market Growth 2023-2029
... at a CAGR of 4.8% from 2023 to 2029. United States market for Enbrel (Etanercept) Biosimilar is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % ... Read More
Research Assistance
